CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Celldex Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Celldex Therapeutics, Inc.
53 Frontage Road, Suite 220
Phone: (908) 200-7500p:908 200-7500 HAMPTON, NJ  08827  United States Ticker: CLDXCLDX

Business Summary
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Karen L.Shoos 69 6/1/2019 5/1/2001
President, Chief Executive Officer, Director Anthony S.Marucci 61 12/4/2008 3/7/2008
Chief Financial Office, Senior Vice President, Secretary SamMartin 52 7/1/2017 1/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CuraGen Corporation 322 East Main Street Branford CT United States
Kolltan Pharmaceuticals Inc 300 George St Ste 530 NEW HAVEN CT United States

Business Names
Business Name
Celldex Therapeutics Switzerland GmbH
CLDX
Kolltan Pharmaceuticals Inc

General Information
Number of Employees: 160 (As of 12/31/2023)
Outstanding Shares: 64,403,377 (As of 2/29/2024)
Shareholders: 133
Stock Exchange: NASD
Federal Tax Id: 133191702
Fax Number: (302) 655-5049
Email Address: info@avantimmune.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024